Literature DB >> 31636067

DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones.

Nathalie Saint-Lu1, Charles Burdet2,3, Frédérique Sablier-Gallis1, Tanguy Corbel1, Agathe Nevière1, Sakina Sayah-Jeanne1, Mark Pulse4, William Weiss4, Stéphanie Ferreira5, Antoine Andremont2, France Mentré2,3, Jean de Gunzburg6.   

Abstract

Fluoroquinolone treatments induce dysbiosis of the intestinal microbiota, resulting in loss of resistance to colonization by exogenous bacteria such as Clostridioides difficile that may cause severe diarrhea in humans and lethal infection in hamsters. We show here that DAV131A, a charcoal-based adsorbent, decreases the intestinal levels of the fluoroquinolone antibiotics levofloxacin and ciprofloxacin in hamsters, protects their intestinal microbiota, and prevents lethal infection by C. difficile.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Clostridioides difficile infection; antibiotics; dysbiosis; fluoroquinolones; hamster animal model; prevention

Year:  2019        PMID： 31636067      PMCID： PMC7187614          DOI： 10.1128/AAC.01196-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis.

Authors:  Charles Burdet; Sakina Sayah-Jeanne; Thu Thuy Nguyen; Christine Miossec; Nathalie Saint-Lu; Mark Pulse; William Weiss; Antoine Andremont; France Mentré; Jean de Gunzburg
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.

Authors:  Kevin A Brown; Nagham Khanafer; Nick Daneman; David N Fisman
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

3.  Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.

Authors:  Jean de Gunzburg; Annie Ducher; Christiane Modess; Danilo Wegner; Stefan Oswald; Jennifer Dressman; Violaine Augustin; Céline Feger; Antoine Andremont; Werner Weitschies; Werner Siegmund
Journal:  J Clin Pharmacol       Date:  2014-07-16       Impact factor: 3.126

Review 4.  Community-associated Clostridium difficile infection and antibiotics: a meta-analysis.

Authors:  Abhishek Deshpande; Vinay Pasupuleti; Priyaleela Thota; Chaitanya Pant; David D K Rolston; Thomas J Sferra; Adrian V Hernandez; Curtis J Donskey
Journal:  J Antimicrob Chemother       Date:  2013-04-25       Impact factor: 5.790

5.  Development of antimicrobial resistance in the normal anaerobic microbiota during one year after administration of clindamycin or ciprofloxacin.

Authors:  Mamun-Ur Rashid; Andrej Weintraub; Carl Erik Nord
Journal:  Anaerobe       Date:  2014-10-15       Impact factor: 3.331

Review 6.  Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance.

Authors:  Victoire de Lastours; Bruno Fantin
Journal:  Future Microbiol       Date:  2015-06-29       Impact factor: 3.165

7.  Burden of Clostridium difficile infection in the United States.

Authors:  Fernanda C Lessa; Yi Mu; Wendy M Bamberg; Zintars G Beldavs; Ghinwa K Dumyati; John R Dunn; Monica M Farley; Stacy M Holzbauer; James I Meek; Erin C Phipps; Lucy E Wilson; Lisa G Winston; Jessica A Cohen; Brandi M Limbago; Scott K Fridkin; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

Review 8.  Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.

Authors:  Claudia Slimings; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2013-12-08       Impact factor: 5.790

Review 9.  Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis.

Authors:  Konstantinos Z Vardakas; Kyriakos K Trigkidis; Eleni Boukouvala; Matthew E Falagas
Journal:  Int J Antimicrob Agents       Date:  2016-04-27       Impact factor: 5.283

10.  Protection of the Human Gut Microbiome From Antibiotics.

Authors:  Jean de Gunzburg; Amine Ghozlane; Annie Ducher; Emmanuelle Le Chatelier; Xavier Duval; Etienne Ruppé; Laurence Armand-Lefevre; Frédérique Sablier-Gallis; Charles Burdet; Loubna Alavoine; Elisabeth Chachaty; Violaine Augustin; Marina Varastet; Florence Levenez; Sean Kennedy; Nicolas Pons; France Mentré; Antoine Andremont
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226
View more
  1 in total

1.  An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.

Authors:  Maria J G T Vehreschild; Annie Ducher; Thomas Louie; Oliver A Cornely; Celine Feger; Aaron Dane; Marina Varastet; Fabien Vitry; Jean de Gunzburg; Antoine Andremont; France Mentré; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.